3T2 Stock Overview An in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
T2 Biosystems, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for T2 Biosystems Historical stock prices Current Share Price US$0.35 52 Week High US$6.00 52 Week Low US$0.28 Beta 0.39 1 Month Change -29.58% 3 Month Change -78.53% 1 Year Change n/a 3 Year Change -99.98% 5 Year Change -99.99% Change since IPO -100.00%
Recent News & Updates
T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally Dec 18
T2 Biosystems Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2) Dec 14
T2 Biosystems, Inc., Annual General Meeting, Dec 30, 2024 Nov 11
T2 Biosystems Receives Letter from the Nasdaq Regarding Listing Rule 5550(b)(2) Nov 08
T2 Biosystems, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Nov 05
T2 Biosystems, Inc. Provides Revenue Guidance for the Fourth Quarter 2024 Oct 07 See more updates
T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally Dec 18
T2 Biosystems Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2) Dec 14
T2 Biosystems, Inc., Annual General Meeting, Dec 30, 2024 Nov 11
T2 Biosystems Receives Letter from the Nasdaq Regarding Listing Rule 5550(b)(2) Nov 08
T2 Biosystems, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Nov 05
T2 Biosystems, Inc. Provides Revenue Guidance for the Fourth Quarter 2024 Oct 07
T2 Biosystems, Inc. Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients Sep 17
T2 Biosystems, Inc. to Report Q2, 2024 Results on Jul 29, 2024 Jul 23 T2 Biosystems, Inc. has filed a Follow-on Equity Offering in the amount of $14.658742 million. Jul 20
T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements May 24
T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements May 23 T2 Biosystems, Inc. announced that it expects to receive $8.000002 million in funding May 16
T2 Biosystems, Inc. has withdrawn its Follow-on Equity Offering. May 15
T2 Biosystems, Inc. to Report Q1, 2024 Results on May 06, 2024 Apr 26 T2 Biosystems, Inc. has filed a Follow-on Equity Offering. Apr 23
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates
T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement Mar 13
T2 Biosystems Announces Agreement with CRG for Conversion of Term Loan into Equity to Regain Compliance Feb 18
T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel Feb 14
T2 Biosystems, Inc. to Report Q4, 2023 Results on Feb 15, 2024 Feb 08
T2 Biosystems Announces Participation in NIH-Funded Antibacterial Resistance Leadership Group (Arlg) Pilot Study for Pneumonia Patients Jan 19
T2 Biosystems, Inc. Announces the Resignation of Thierry Bernard as Class II Director and All Committees of the Board of Directors Jan 06
The Nasdaq Listing Qualifications Staff Issues Delist Determination to T2 Biosystems Nov 27
The Nasdaq Listing Qualifications Staff Issues Delist Determination to T2 Biosystems Nov 26
T2 Biosystems, Inc. announced delayed 10-Q filing Nov 17
T2 Biosystems, Inc. Highlights New Clinical Data Presented At IDWeek 2023 Conference Oct 26
T2 Biosystems Provides Nasdaq Compliance Update Oct 14
T2 Biosystems, Inc. to Report Q3, 2023 Results on Oct 12, 2023 Oct 06
T2 Biosystems Receives FDA 510(k) Clearance for the T2Biothreat Panel Sep 21
T2 Biosystems, Inc. Updates Revenue Guidance for the Year 2023 Aug 12
T2 Biosystems Regains Compliance with Nasdaq’s Market Value of Listed Securities Requirement Aug 10
T2 Biosystems Receives Extension through November 20, 2023 to Comply with Nasdaq's Minimum Bid Price and Market Value of Listed Securities Requirements Aug 01
T2 Biosystems, Inc., Annual General Meeting, Sep 12, 2023 Jul 28
T2 Biosystems, Inc. to Report Q2, 2023 Results on Aug 07, 2023 Jul 25
T2 Biosystems, Inc. Receives FDA Breakthrough Device Designation for Candida Auris Diagnostic Test Jul 23
T2 Biosystems, Inc. Provides Revenue Guidance for the Year 2023 Jul 13 T2 Biosystems, Inc. announced that it has received $0.1 million in funding from CR Group L.P. Jul 07
T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for Candida Auris Diagnostic Test Jun 06 T2 Biosystems Receives Letter from Nasdaq Regarding its Shares Failure to Comply with the Market Value of Listed Securities Required for Continued Listing on The Nasdaq Capital Market
T2 Biosystems, Inc. announced delayed 10-Q filing May 16
Full year 2022 earnings released: US$12.15 loss per share (vs US$15.50 loss in FY 2021) Mar 18 T2 Biosystems, Inc. has completed a Follow-on Equity Offering in the amount of $12 million. Feb 17
T2 Biosystems, Inc. has completed a Follow-on Equity Offering. Feb 16
T2 Biosystems, Inc. Announces Positive Results Upon Completion of U.S. Clinical Evaluation for the T2Biothreat Panel Feb 15
T2 Biosystems Inc. Advances to the Phase 2 in HHS and the Steven and Alexandra Cohen Foundation's LymeX Diagnostics Prize Feb 07
Third quarter 2022 earnings released: US$2.95 loss per share (vs US$4.21 loss in 3Q 2021) Nov 19
High number of new directors Nov 17
T2 Biosystems, Inc. Announces Resignation of Alec Barclay as Chief Operations Officer, Effective November 30, 2022 Nov 08
T2 Biosystems Regains Compliance with Nasdaq’s Minimum Bid Price Rule Nov 02
T2 Biosystems, Inc. to Report Q3, 2022 Results on Nov 10, 2022 Nov 01
T2 Biosystems, Inc. Initiates Studies to Add Acinetobacter Baumannii to the FDA-Cleared T2Bacteria Panel Oct 21
T2 Biosystems, Inc. Announces Plan to Commercialize A Diagnostic Test for Early Lyme Disease Oct 14
T2 Biosystems, Inc. Updates Revenue Outlook for the Full Year of 2022 Oct 13 T2 Biosystems, Inc. Announces BARDA Exercise of Contract Option 3 Valued at $3.7 Million Sep 30
T2 Biosystems, Inc., Annual General Meeting, Oct 11, 2022 T2 Biosystems, Inc. announced delayed 10-Q filing Aug 17
T2 Biosystems, Inc to Explore Potential to Develop Rapid Molecular Diagnostic Test for Monkeypox Virus Aug 11
T2 Biosystems, Inc. to Report Q2, 2022 Results on Aug 15, 2022 Jul 29
T2 Biosystems Receives Non-Compliance Notice from Nasdaq Jul 26
T2 Biosystems, Inc. Receives Food and Drug Administration Breakthrough Device Designation for the T2Lyme Panel Jul 12
T2 Biosystems, Inc. Provides Preliminary Unaudited Revenue Guidance for the Quarter Ended June 30, 2022 and Provides Revenue Guidance for the Full Year 2022 Jul 07
T2 Biosystems Receives Nasdaq Extension to Comply with Bid Price Rule Jun 11
High number of new directors Jun 01
First quarter 2022 earnings released: US$0.097 loss per share (vs US$0.072 loss in 1Q 2021) May 13
T2 Biosystems Announces Receipt of Nasdaq Delisting Notice May 06
High number of new directors May 02
T2 Biosystems, Inc. Submits Application with U.S. Food and Drug Administration for Breakthrough Device Designation for T2Biothreat Panel Apr 28
No longer forecast to breakeven Apr 27
T2 Biosystems, Inc. to Report Q1, 2022 Results on May 05, 2022 Apr 22
T2 Biosystems, Inc. Announces Revenue Guidance for the Full Year of 2022 Apr 13
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 19
No longer forecast to breakeven Feb 18
T2 Biosystems, Inc. Provides Earnings Guidance for the Year 2022 Feb 18
T2 Biosystems, Inc. to Report Q4, 2021 Results on Feb 17, 2022 Feb 09
T2 Biosystems Announces the Initiation of the T2Biothreat® Panel Clinical Trial Jan 12 Shareholder Returns 3T2 DE Biotechs DE Market 7D -1.1% 2.4% -0.4% 1Y n/a -10.2% 7.9%
See full shareholder returns
Return vs Market: Insufficient data to determine how 3T2 performed against the German Market .
Price Volatility Is 3T2's price volatile compared to industry and market? 3T2 volatility 3T2 Average Weekly Movement 24.8% Biotechs Industry Average Movement 7.3% Market Average Movement 4.9% 10% most volatile stocks in DE Market 12.1% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 3T2's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 3T2's weekly volatility has increased from 18% to 25% over the past year.
About the Company T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens.
Show more T2 Biosystems, Inc. Fundamentals Summary How do T2 Biosystems's earnings and revenue compare to its market cap? 3T2 fundamental statistics Market cap €8.17m Earnings (TTM ) -€41.68m Revenue (TTM ) €7.45m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 3T2 income statement (TTM ) Revenue US$7.68m Cost of Revenue US$26.70m Gross Profit -US$19.03m Other Expenses US$23.93m Earnings -US$42.95m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -2.04 Gross Margin -247.83% Net Profit Margin -559.52% Debt/Equity Ratio -101.8%
How did 3T2 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/03 11:35 End of Day Share Price 2025/01/03 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources T2 Biosystems, Inc. is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Benjamin Haynor Alliance Global Partners Karen Koski BTIG Kyle Mikson Canaccord Genuity
Show 7 more analysts 
